{"id":824266,"date":"2025-03-11T08:48:45","date_gmt":"2025-03-11T12:48:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/"},"modified":"2025-03-11T08:48:45","modified_gmt":"2025-03-11T12:48:45","slug":"moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/","title":{"rendered":"Moleculin Biotech, Inc. Participates in the Virtual Investor “Top 5 for ’25” On-Demand Conference"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n On-demand video webcast now available here<\/a>
\n <\/i>\n <\/p>\n

\n
\n HOUSTON<\/span>
\n <\/span>, March 11, 2025<\/span><\/span> \/PRNewswire\/ — Moleculin Biotech, Inc.<\/b>,\u00a0(Nasdaq: MBRX) (“Moleculin” or the “Company”) a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it participated in the Virtual Investor “Top 5 for ’25” On-Demand Conference<\/a>.<\/p>\n

\n

\n
\n \"(PRNewsfoto\/Moleculin
\n <\/a>\n <\/p>\n<\/p><\/div>\n

As part of the event, Walter Klemp<\/span>, Chairman and Chief Executive Officer of Moleculin, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to Moleculin in 2025.<\/p>\n

The on-demand video webcast is now accessible for viewing\u00a0here<\/a> and on the Events<\/a> page in the Investors<\/a> section of the Company’s website (moleculin.com<\/a>).<\/p>\n

\n About Moleculin Biotech, Inc.<\/b>\n <\/p>\n

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.<\/p>\n

The Company is initiating the MIRACLE (Moleculin R\/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B<\/span>\/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study is subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.<\/p>\n

Additionally, the Company is developing WP1066, an Immune\/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.
For more information about the Company, please visit www.moleculin.com<\/a> and connect on X<\/a>, LinkedIn<\/a> and Facebook<\/a>.<\/p>\n

\n Investor Contact:<\/b>
\n
JTC Team, LLC
Jenene Thomas<\/span>
(908) 824-0775
MBRX@jtcir.com<\/a><\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference-302397299.html<\/a><\/p>\n

SOURCE Moleculin Biotech, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire On-demand video webcast now available here HOUSTON , March 11, 2025 \/PRNewswire\/ — Moleculin Biotech, Inc.,\u00a0(Nasdaq: MBRX) (“Moleculin” or the “Company”) a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it participated in the Virtual Investor “Top 5 for ’25” On-Demand Conference. As part of the event, Walter Klemp, Chairman and Chief Executive Officer of Moleculin, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to Moleculin in 2025. The on-demand video webcast is now accessible for viewing\u00a0here and on the Events page in the Investors section of the Company’s website (moleculin.com). About Moleculin Biotech, Inc. Moleculin Biotech, Inc. is … <\/p>\n

Continue reading “Moleculin Biotech, Inc. Participates in the Virtual Investor “Top 5 for ’25” On-Demand Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-824266","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMoleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire On-demand video webcast now available here HOUSTON , March 11, 2025 \/PRNewswire\/ — Moleculin Biotech, Inc.,\u00a0(Nasdaq: MBRX) (“Moleculin” or the “Company”) a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it participated in the Virtual Investor “Top 5 for ’25” On-Demand Conference. As part of the event, Walter Klemp, Chairman and Chief Executive Officer of Moleculin, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to Moleculin in 2025. The on-demand video webcast is now accessible for viewing\u00a0here and on the Events page in the Investors section of the Company’s website (moleculin.com). About Moleculin Biotech, Inc. Moleculin Biotech, Inc. is … Continue reading "Moleculin Biotech, Inc. Participates in the Virtual Investor “Top 5 for ’25” On-Demand Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-11T12:48:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/959635\/Moleculin_Biotech_Inc_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Moleculin Biotech, Inc. Participates in the Virtual Investor “Top 5 for ’25” On-Demand Conference\",\"datePublished\":\"2025-03-11T12:48:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/\"},\"wordCount\":398,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/959635\\\/Moleculin_Biotech_Inc_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/\",\"name\":\"Moleculin Biotech, Inc. Participates in the Virtual Investor \\\"Top 5 for '25\\\" On-Demand Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/959635\\\/Moleculin_Biotech_Inc_Logo.jpg\",\"datePublished\":\"2025-03-11T12:48:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/959635\\\/Moleculin_Biotech_Inc_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/959635\\\/Moleculin_Biotech_Inc_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Moleculin Biotech, Inc. Participates in the Virtual Investor “Top 5 for ’25” On-Demand Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Moleculin Biotech, Inc. Participates in the Virtual Investor \"Top 5 for '25\" On-Demand Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/","og_locale":"en_US","og_type":"article","og_title":"Moleculin Biotech, Inc. Participates in the Virtual Investor \"Top 5 for '25\" On-Demand Conference - Market Newsdesk","og_description":"PR Newswire On-demand video webcast now available here HOUSTON , March 11, 2025 \/PRNewswire\/ — Moleculin Biotech, Inc.,\u00a0(Nasdaq: MBRX) (“Moleculin” or the “Company”) a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it participated in the Virtual Investor “Top 5 for ’25” On-Demand Conference. As part of the event, Walter Klemp, Chairman and Chief Executive Officer of Moleculin, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to Moleculin in 2025. The on-demand video webcast is now accessible for viewing\u00a0here and on the Events page in the Investors section of the Company’s website (moleculin.com). About Moleculin Biotech, Inc. Moleculin Biotech, Inc. is … Continue reading \"Moleculin Biotech, Inc. Participates in the Virtual Investor “Top 5 for ’25” On-Demand Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-11T12:48:45+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/959635\/Moleculin_Biotech_Inc_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Moleculin Biotech, Inc. Participates in the Virtual Investor “Top 5 for ’25” On-Demand Conference","datePublished":"2025-03-11T12:48:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/"},"wordCount":398,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/959635\/Moleculin_Biotech_Inc_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/","name":"Moleculin Biotech, Inc. Participates in the Virtual Investor \"Top 5 for '25\" On-Demand Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/959635\/Moleculin_Biotech_Inc_Logo.jpg","datePublished":"2025-03-11T12:48:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/959635\/Moleculin_Biotech_Inc_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/959635\/Moleculin_Biotech_Inc_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Moleculin Biotech, Inc. Participates in the Virtual Investor “Top 5 for ’25” On-Demand Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/824266","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=824266"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/824266\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=824266"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=824266"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=824266"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}